Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety extension study of iclepertin in schizophrenia
NL-OMON60975Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2024
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of iclepertin in schizophrenia, sponsored by Boehringer Ingelheim. Primary endpoint: Occurrence of treatment emergent adverse events. Started Oct 2024; status: completed.
02
Drugs
iclepertin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NL-OMON60975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60975.